Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ C4502997!4502997!26191125     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Clin+Exp+Pathol 2015 ; 8 (5): 4332-43 Nephropedia Template TP {{tp|p=26191125|t=2015. Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis |pdf=|usr=}}{{26191125}} gab.com Text Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis JO: Int J Clin Exp Pathol http://www.kidney.de/pget.php?&tw=1&pmid=26191125 #FOAvip Hyperlipidemic pancreatitis (HP) is a serious inflammatory disease with very high mortality and multiple organ injuries including renal injury. Rosiglitazone (Ros), an agonist of peroxisome proliferator activated receptor-? (PPAR-?), was reported to show a protective role against pancreatitis. However, whether Ros has an effect on renal injury caused by HP is not yet clear. In the present study, the function of Ros was explored using ELISA, RT-PCR, western blot, PAS staining and immunohistochemistry. Results of this study showed that Ros could inhibit the activation of NF-?B and MAPK P38 signaling pathways, relieve inflammatory response and inhibit cell apoptosis, thus attenuating renal injury caused by HP. This study suggested that Ros might be a promising drug for the treatment of renal injury caused by HP and also laid theoretical foundation for the development of renal injury treatment. Twit Text FOAVip Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis ????Int J Clin Exp Pathol http://www.kidney.de/pget.php?&tw=1&pmid=26191125 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26191125 #FOAvip English Wikipedia <ref>{{Cite pmid|26191125}}</ref> Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis #MMPMID26191125 Wang R; Yan Z; Wu X; Ji K; Wang H; Zang B Int J Clin Exp Pathol 2015[]; 8 (5): 4332-43 PMID26191125show ga Hyperlipidemic pancreatitis (HP) is a serious inflammatory disease with very high mortality and multiple organ injuries including renal injury. Rosiglitazone (Ros), an agonist of peroxisome proliferator activated receptor-? (PPAR-?), was reported to show a protective role against pancreatitis. However, whether Ros has an effect on renal injury caused by HP is not yet clear. In the present study, the function of Ros was explored using ELISA, RT-PCR, western blot, PAS staining and immunohistochemistry. Results of this study showed that Ros could inhibit the activation of NF-?B and MAPK P38 signaling pathways, relieve inflammatory response and inhibit cell apoptosis, thus attenuating renal injury caused by HP. This study suggested that Ros might be a promising drug for the treatment of renal injury caused by HP and also laid theoretical foundation for the development of renal injury treatment. äRosiglitazone attenuates renal injury caused by hyperlipidemic pancrea(epmc).pdf DeepDyve Pubget Overpricing